Senores Pharmaceuticals credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025

327	327	305
167	167	−80.7
0.34×	0.34×	0.38×
0.17×	0.17×	−0.10×
1.94×	1.94×	3.40×
0.79×	1.00×	−0.90×
5.48×	5.48×	3.38×
24.1%	25.3%	27.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SENORES₹1,219.20

Senores Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersSANOFI INNOVACAP MOREPENLAB IOLCP FDC PGHL SANOFICONR ORCHPHARMAMcap ₹5,614 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Total Debt	304.8	327.1	327.1
Net Debt	-80.7	167.5	167.5
Total Debt/Equity	0.38	0.34	0.34
Net Debt/Equity	-0.10	0.17	0.17
Total Debt/EBITDA	3.40	1.94	1.94
Net Debt/EBITDA	-0.90	1.00	0.79
Interest Coverage (EBIT/Interest)	3.38	5.48	5.48
Total Debt/Total Capital %	27.28	25.32	24.08

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.